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Background: Nonpolymeric drug-eluting stents (DES) have arisen as an attractive alternative to minimize local inflammatory reactions and 
potentially reduce the adverse events observed following the 1st generation of DES with thick, durable polymers. We sought to assess the long term 
efficacy of the novel VESTAsync™ Eluting Stent (VES) combining a Cro-Co platform with a nanothin-microporous hydroxyapatite surface coating 
impregnated with a polymer-free low-dose of Sirolimus (55μg).
Methods: The Vestasync II trial was a randomized (2:1), double-blinded, multicenter comparison of the VES to its platform, the Gen X stent, with 
microporous hydroxyapatite surface coating but without sirolimus. Patients were eligible if they presented single de novo lesions in native coronary 
arteries with 3.0-3.5mm diameter and ≤ 14mm in length. Primary endpoint was 9-month in-stent late loss and % of stent obstruction. Lifelong AAS 
and 6-month clopidogrel were prescribed to all pts.
Results: Seventy-five patients were enrolled (VES = 50pts). Baseline characteristics did not differ between groups and included mean age of 58 
years and 29% of diabetics. Angiographic characteristics including RVD (2.8 ± 0.4mm) and lesion length (13.0 ± 2.0mm)also did not significant 
differ for the 2 groups. Procedure success was obtained in all cases. All patients underwent invasive FU at 9 months. In-stent LL (0.39 ± 0.20 vs. 
0.74 ± 0.52, p=0.03) and IVUS % of NIH (9.3 ± 6.6% vs. 17.6 ± 9.4%, p=0.0016)were significantly reduced in the VES cohort. Up to two years there 
was 1 case of MI (periprocedure non-Q wave MI) and 1 TLR (2%) in the VES group, while in the control cohort there were 2 TLR (8%) and 1 cardiac 
death (4%). Of note, after the 1st year there were no events in both groups. Three-year clinical FU data will be available during the meeting.
Conclusion: The VestSync II trial was a proof-of-concept study and demonstrated the sustained efficacy of this novel polymer-free sirolimus DES. A 
larger trial, with more complex lesions, clinical endpoints and longer FU period is warranted
